170 related articles for article (PubMed ID: 29949489)
1. Metastasis-free Survival - A New End Point in Prostate Cancer Trials.
Beaver JA; Kluetz PG; Pazdur R
N Engl J Med; 2018 Jun; 378(26):2458-2460. PubMed ID: 29949489
[No Abstract] [Full Text] [Related]
2. FDA Approves First Treatment for Nonmetastatic, Castration-Resistant Prostate Cancer.
Aschenbrenner DS
Am J Nurs; 2018 Jun; 118(6):26. PubMed ID: 29794918
[No Abstract] [Full Text] [Related]
3. Apalutamide shows efficacy in prostate cancer.
Gourd E
Lancet Oncol; 2018 Mar; 19(3):e149. PubMed ID: 29456088
[No Abstract] [Full Text] [Related]
4. Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer.
Pilon D; Ellis LA; Xiao Y; Behl AS; Lefebvre P
Am J Ther; 2019; 26(3):e422-e424. PubMed ID: 30677005
[No Abstract] [Full Text] [Related]
5. [Apalutamide for metastatic, castration-sensitive prostate cancer].
Thomas C
Urologe A; 2019 Dec; 58(12):1496-1497. PubMed ID: 31712857
[No Abstract] [Full Text] [Related]
6. Solid cancer: the new tumour spread endpoint opens novel opportunities.
Fernandes M; Rosel D; Brábek J
Br J Cancer; 2019 Oct; 121(7):513-514. PubMed ID: 31427682
[TBL] [Abstract][Full Text] [Related]
7. New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival?
Di Nunno V; Santoni M; Massari F
Eur Urol Oncol; 2019 Jul; 2(4):471. PubMed ID: 31277785
[No Abstract] [Full Text] [Related]
8. [A multicentric, randomized, double-blind, placebo-controlled Phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer (SPARTAN): AUO study AP 82/14].
Rexer H; Hammerer P
Urologe A; 2016 Mar; 55(3):395-7. PubMed ID: 26820656
[No Abstract] [Full Text] [Related]
9. Use of radium-223 in men with metastatic castration-resistant prostate cancer.
Parker C
Clin Adv Hematol Oncol; 2015 Nov; 13(11):723-5. PubMed ID: 27058695
[No Abstract] [Full Text] [Related]
10. Apalutamide: First Global Approval.
Al-Salama ZT
Drugs; 2018 Apr; 78(6):699-705. PubMed ID: 29626324
[TBL] [Abstract][Full Text] [Related]
11. Apalutamide (Erleada) for prostate cancer.
Med Lett Drugs Ther; 2018 Jul; 60(1551):e124-e125. PubMed ID: 30036351
[No Abstract] [Full Text] [Related]
12. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary.
Kluetz PG; Ning YM; Maher VE; Zhang L; Tang S; Ghosh D; Aziz R; Palmby T; Pfuma E; Zirkelbach JF; Mehrotra N; Tilley A; Sridhara R; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2013 Dec; 19(24):6650-6. PubMed ID: 24150234
[TBL] [Abstract][Full Text] [Related]
13. Castration-naive metastatic prostate cancer: reshaping old paradigms.
Ratta R; Grassi P; Fucà G; Verzoni E; Procopio G
Expert Rev Anticancer Ther; 2017 Oct; 17(10):879-881. PubMed ID: 28854837
[No Abstract] [Full Text] [Related]
14. [New treatment option-apalutamide for nonmetastatic, castration-resistant prostate cancer].
Hadaschik B; Panic A
Urologe A; 2018 Jun; 57(6):729-730. PubMed ID: 29789876
[No Abstract] [Full Text] [Related]
15. Drug therapies for metastatic castration-resistant prostate cancer.
El-Bahesh E; Finianos A; Alfaraj A; Aragon-Ching JB
Future Oncol; 2015; 11(17):2395-403. PubMed ID: 26274603
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival.
Francini E; Fiaschi AI; Petrioli R; Bianco V; Laera L; Francini F; Roviello G
Anticancer Drugs; 2015 Sep; 26(8):910-1. PubMed ID: 26207428
[No Abstract] [Full Text] [Related]
17. Novel Nonsteroidal Antiandrogens and Overall Survival in Nonmetastatic Castration-resistant Prostate Cancer.
Bhindi B; Karnes RJ
Eur Urol; 2018 Oct; 74(4):534-535. PubMed ID: 29866462
[No Abstract] [Full Text] [Related]
18. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
Dreicer R
Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
[No Abstract] [Full Text] [Related]
19. How I do it: Apalutamide use in non-metastatic castrate resistant prostate cancer.
Moul JW
Can J Urol; 2019 Jun; 26(3):9782-9786. PubMed ID: 31180310
[TBL] [Abstract][Full Text] [Related]
20. Metastatic castration-resistant prostate cancer: integrating new learnings to optimise treatment outcomes.
Heidenreich A; Porres D; Piper C; Thissen AK; Pfister D
Minerva Urol Nefrol; 2013 Sep; 65(3):171-87. PubMed ID: 23872628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
